Scholarlink

<p>Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows promise in managing obesity and type 2 diabetes. This bibliometric analysis maps its research landscape, identifying trends, collaborations, and emerging themes to guide future investigations. A structured search of the Scopus database was performed using the keywords “tirzepatide” in titles or abstracts, limited to English-language original articles. A total of 446 documents were retrieved. Bibliometric analysis was conducted using VOSviewer (v1.6.19), Biblioshiny (Rstudio plugin), and CiteSpace (v6.2.R6) to visualize co-authorship, keyword co-occurrence, citation patterns, and thematic evolution. Tirzepatide publications peaked in 2024 (<i>n</i> = 163), with the USA leading (<i>n</i> = 243, 10,076 citations). Key authors included Urva, S. and Haupt, A. Three thematic clusters emerged: pharmacological mechanisms, clinical outcomes, and study design. Emerging topics included weight reduction, pharmacovigilance, and cost-effectiveness. Co-citation analysis identified four author clusters, with Frias J.P. (TLS = 13,605) most influential. Journals like Diabetes, Obesity and Metabolism dominated. Thematic evolution showed shifts toward real-world evidence and metabolic dysfunction-associated steatotic liver disease, reflecting broadening research scope. Tirzepatide research is growing globally with diverse collaborations, informing future therapeutic strategies and highlighting gaps in long-term safety, accessibility, and cost-effectiveness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements

  • 期刊论文

  • 发表日期：

    2025年9月3日

查看全文
  • Manal Mohamed Elhassan Taha,
  • Siddig Ibrahim Abdelwahab,
  • Omar Oraibi,
  • Mohammed A. Madkhali,
  • Abdulhameed Albarraq Alhazmi,
  • Mohammed Jeraiby,
  • Saleh M. Abdullah,
  • Abdullah Farasani,
  • Jobran M. Moshi,
  • Nizar A. Khamjan,
  • Saeed Alshahrani,
  • Hussam M. Shubaily,
  • Khaled A. Sahli,
  • Marwa Qadri,
  • Amani Khardali

摘要

Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows promise in managing obesity and type 2 diabetes. This bibliometric analysis maps its research landscape, identifying trends, collaborations, and emerging themes to guide future investigations. A structured search of the Scopus database was performed using the keywords “tirzepatide” in titles or abstracts, limited to English-language original articles. A total of 446 documents were retrieved. Bibliometric analysis was conducted using VOSviewer (v1.6.19), Biblioshiny (Rstudio plugin), and CiteSpace (v6.2.R6) to visualize co-authorship, keyword co-occurrence, citation patterns, and thematic evolution. Tirzepatide publications peaked in 2024 (n = 163), with the USA leading (n = 243, 10,076 citations). Key authors included Urva, S. and Haupt, A. Three thematic clusters emerged: pharmacological mechanisms, clinical outcomes, and study design. Emerging topics included weight reduction, pharmacovigilance, and cost-effectiveness. Co-citation analysis identified four author clusters, with Frias J.P. (TLS = 13,605) most influential. Journals like Diabetes, Obesity and Metabolism dominated. Thematic evolution showed shifts toward real-world evidence and metabolic dysfunction-associated steatotic liver disease, reflecting broadening research scope. Tirzepatide research is growing globally with diverse collaborations, informing future therapeutic strategies and highlighting gaps in long-term safety, accessibility, and cost-effectiveness.